Menarini Biotech (“MBH”) is a fast-growing, agile, fully integrated CDMO for biologics. Established in 2003, MBH's mission is to provide fast and efficient, yet very customer-centric, world-class, high-quality, services for biotech companies. Our Q system complies with AIFA/EU GMP requirements.
Products, services, technology
Process-related impurities/Contaminants - Product-related impurities - Protein characterisation - Comparability Study - Stability Study - Forced Degradation Study - Validation of Analytical Methods - Batch Certification - Established Analytical and DSP Platforms - Formulation Development - Aseptic Filling - Bioconjugation
Preclinical development - Analytical development - Cell line development (CLD) - GMP manufacturing (Mammalian and Microbial) for (non)-standard mAbs, and new molecular formats, e.g. bispecifics, ADCs, fusion proteins
Millions of people die every year because of the lack of appropriate medicine or missing access to the right treatment.
Menarini Biotech as an agile CDMO for emerging biotech companies help advance new medicines for those in need to be treated where and when they need it the most.
Menarini Biotech has provided services mainly for captive use. It's a hidden gem. These services are now available to biotech companies as Menarini Biotech is a CDMO with > 20 years of experience.
Jennifer Doudna with CRISPR/Cas9
Stephane Bancel, CEO Moderna, going from no commercial product to being on the forefront of commercial mRNA vaccie supply for the world
Robert A. Swanson and Herbert W. Boyer, the founders of Genentech, the first and most successful biotech company
Core strengths include:
- customer centricity
Looking to integrate:
My Dad is very good at selling. He comes across super friendly and forthcoming to any prospective clients. He loves his job and is happy to share his experience.
Providing a platform across Switzerland and beyond to exchange with other KOLs in the biotech industry by means of:
- networking events